Imunon (IMNN) News Today $0.83 -0.02 (-2.83%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Imunon announces positive outcome of Type C CMC meeting with FDA on IMNN-001December 20 at 12:18 PM | markets.businessinsider.comImunon, Inc.: IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian CancerDecember 19 at 1:10 PM | finanznachrichten.deIMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian CancerDecember 19 at 8:05 AM | globenewswire.comImunon announces additional data from results from Phase 2 OVATION 2 studyDecember 11, 2024 | markets.businessinsider.comStrong Potential for Imunon’s IMNN-001 in Advanced Ovarian Cancer: Promising OVATION 2 Study ResultsDecember 11, 2024 | markets.businessinsider.comIMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001December 10, 2024 | globenewswire.comImunon Receives Buy Rating Amid Promising Phase 3 Trial Prospects for IMNN-001 in Advanced Ovarian CancerNovember 27, 2024 | markets.businessinsider.comIMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…November 26, 2024 | msn.comIMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian CancerNovember 25, 2024 | globenewswire.comIMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer TrialNovember 11, 2024 | finance.yahoo.comImunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...November 8, 2024 | finance.yahoo.comImunon presents data from Phase 2 OVATION 2 clinical trialNovember 7, 2024 | markets.businessinsider.comImunon, Inc. (IMNN) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comImunon Announces Positive Data From Phase 2 Trial Of IMNN-001 In Advanced Ovarian Cancer, Stock DownNovember 7, 2024 | markets.businessinsider.comIMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual MeetingNovember 7, 2024 | globenewswire.comIMUNON Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 7, 2024 | globenewswire.comImunon (IMNN) Scheduled to Post Earnings on ThursdayImunon (NASDAQ:IMNN) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comImunon to present Phase 2 data of IMNN-001October 31, 2024 | markets.businessinsider.comIMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024October 31, 2024 | globenewswire.comIMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual MeetingOctober 30, 2024 | globenewswire.comImunon reports inducement grant under NASDAQ listing ruleOctober 8, 2024 | finance.yahoo.comIMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)October 7, 2024 | globenewswire.comImunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy"EF Hutton Acquisition Co. I upgraded shares of Imunon to a "strong-buy" rating in a research note on Monday.September 25, 2024 | marketbeat.comEF Hutton Initiates Coverage of Imunon (IMNN) with Buy RecommendationSeptember 24, 2024 | msn.comUPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive ManagementSeptember 9, 2024 | globenewswire.comIMUNON to Host R&D Day on September 18thAugust 28, 2024 | globenewswire.comInsider Buying: Imunon, Inc. (NASDAQ:IMNN) CEO Buys 25,000 Shares of StockAugust 17, 2024 | insidertrades.comIMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study…August 15, 2024 | msn.comIMUNON Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | globenewswire.comIMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024August 7, 2024 | globenewswire.comImunon Share Price (IMNN.US)August 4, 2024 | lse.co.ukWhy Imunon (IMNN) Stock Is Down 60% TodayJuly 31, 2024 | msn.comImunon’s shares soar after IL-12 therapy success in Phase II trialJuly 31, 2024 | finance.yahoo.comIMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJuly 31, 2024 | finance.yahoo.comImunon Shares More Than Double on Ovarian Cancer Study ResultsJuly 31, 2024 | marketwatch.comImunon (NASDAQ:IMNN) Stock Quotes, Forecast and News SummaryJuly 31, 2024 | benzinga.comNano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer PatientsJuly 31, 2024 | msn.comImunon, Inc.: IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001July 30, 2024 | finanznachrichten.deDow Jumps 200 Points; Pfizer Earnings Top ViewsJuly 30, 2024 | benzinga.comImunon's Advanced Ovarian Cancer Study Data Shows Survival ImprovementJuly 30, 2024 | marketwatch.comImunon’s stock rockets after ovarian cancer treatment’s positive trial resultsJuly 30, 2024 | msn.comWhy Is Imunon (IMNN) Stock Up 259% Today?July 30, 2024 | investorplace.comIMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001July 30, 2024 | globenewswire.comImunon Shares Surge Ahead of Results From Ovarian Cancer Treatment StudyJuly 30, 2024 | marketwatch.comIMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer TomorrowJuly 29, 2024 | globenewswire.comIMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerJune 24, 2024 | globenewswire.comFirst Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical TrialJune 5, 2024 | globenewswire.comIMNN: Results from OVATION 2 Study in Mid-2024…May 16, 2024 | finance.yahoo.comQ1 2024 Imunon Inc Earnings CallMay 15, 2024 | uk.finance.yahoo.comAbstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingMay 15, 2024 | finance.yahoo.com Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW IMNN Media Mentions By Week IMNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNN News Sentiment▼0.500.60▲Average Medical News Sentiment IMNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNN Articles This Week▼51▲IMNN Articles Average Week Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CASI News Today KZR News Today OMGA News Today XCUR News Today ACAB News Today ESLA News Today ALRN News Today VIRI News Today CDIO News Today BIVI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
